Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
April 06, 2023 at 07:01 am EDT
Share
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
Title:
Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor
Presenter:
Jim Cregg, Ph.D.
Abstract Number:
ND07
Session:
New Drugs on the Horizon: Part 2
Date/Time:
3:45 – 4:00 p.m. Eastern on April 16, 2023
Title:
RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
Presenter:
Marie Menard, Ph.D.
Abstract Number:
3475
Session:
Immune Checkpoints at Tumor Beds
Date/Time:
3:37 – 3:52 p.m. Eastern on April 17, 2023
Revolution Medicines Poster Presentations:
Title:
RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Presenter:
Lingyan Jiang, Ph.D.
Abstract Number:
526/26
Session:
Novel Antitumor Agents 2
Date/Time:
1:30 – 5:00 p.m. Eastern on April 16, 2023
Title:
RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
Presenter:
Yu C. Yang, Ph.D.
Abstract Number:
1598/21
Session:
New Therapeutic Targeted Agents
Date/Time:
9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023
Collaborator Oral Presentation:
Title:
Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer
Abstract Number:
5733
Session:
New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Presentation Time:
2:37 – 2:52 p.m. Eastern on April 18, 2023
Collaborator Poster Presentations:
Title:
Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Abstract Number:
LB015/7
Session:
Late-Breaking Research: Experimental and Molecular Therapeutics 1
Presentation Time:
1:30 – 5:00 p.m. Eastern on April 16, 2023
Title:
Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma
Abstract Number:
1725/22
Session:
Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
Date/Time:
9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023
Title:
Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
Abstract Number:
4859/2
Session:
Anticancer Approaches Targeting Signal Transduction Pathways
Presentation Time:
1:30 – 5:00 p.m. Eastern on April 18, 2023
Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2023/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
Contacts:
For Investors & Media:
Erin Graves
650-779-0136
egraves@revmed.com
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.